Business
Prelude Therapeutics Inc: Our pipeline is designed to serve patients with high unmet medical need, where there are limited or no treatment options.
Revenue increased 73.4% to $12.1M, while Net income increased 21.8% to ($99.5M).
The read at a glance✓ Audited against SEC data
- Scale — FY2025 revenue $12.1MWatch
- Profitability — Net income ($99.5M)Watch
- Cash generation — Free cash flow ($56.4M)Note
- Accounting — Formula distress score · manipulation and earnings-quality screens not computedWatch
- Insiders — 2 buys; 0 sells in 365 daysOK
- Capital — Comparable payout data unavailableNote
Leadership changes
From Prelude Therapeutics Inc's own filings, the day they're filed.
- Charles Q. Morris · Chief Medical Officer · appointmenteff. 2026-04-15
- Jane Huang · Chief Medical Officer · departureeff. 2025-11-04
- Prelude Therapeutics Incorporated · Chief Financial Officer · departureeff. 2024-04-10
Latest filings
- 8-K · Company announcement2026-08-11
- 10-Q · Quarterly report2026-08-11
- 8-K · Company announcement2026-06-10
- 10-Q · Quarterly report2026-05-12
- 8-K · Company announcement2026-05-12
In the full recordFree for 14 days
- What changed🔒
- Insider signal🔒
- Growth quality🔒
- Margins & accounting🔒
- Capital allocation🔒
- Real risks🔒
- The long arc🔒
- Company history🔒
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about Prelude Therapeutics Inc, every answer cited to the official filings🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.